Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NEMOLIZUMAB Cause Inappropriate schedule of product administration? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Inappropriate schedule of product administration have been filed in association with NEMOLIZUMAB (NEMLUVIO). This represents 1.9% of all adverse event reports for NEMOLIZUMAB.

7
Reports of Inappropriate schedule of product administration with NEMOLIZUMAB
1.9%
of all NEMOLIZUMAB reports
0
Deaths
3
Hospitalizations

How Dangerous Is Inappropriate schedule of product administration From NEMOLIZUMAB?

Of the 7 reports, 3 (42.9%) required hospitalization.

Is Inappropriate schedule of product administration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NEMOLIZUMAB. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does NEMOLIZUMAB Cause?

Pemphigoid (51) Death (33) Erythema (26) Dermatitis exfoliative generalised (25) Erythema multiforme (25) Dermatitis atopic (23) Pneumonia (14) Blister (12) Cellulitis (12) Eczema herpeticum (12)

What Other Drugs Cause Inappropriate schedule of product administration?

ADAPALENE (16,473) DUPILUMAB (14,927) AVOBENZONE\OCTISALATE\OCTOCRYLENE (12,546) INSULIN GLARGINE (8,982) INFLIXIMAB (6,847) INFLIXIMAB-DYYB (5,977) SECUKINUMAB (4,817) DULAGLUTIDE (3,606) VEDOLIZUMAB (3,259) SACUBITRIL\VALSARTAN (2,870)

Which NEMOLIZUMAB Alternatives Have Lower Inappropriate schedule of product administration Risk?

NEMOLIZUMAB vs NEMOLIZUMAB-ILTO NEMOLIZUMAB vs NEOMYCIN NEMOLIZUMAB vs NEORAL NEMOLIZUMAB vs NEOSTIGMINE NEMOLIZUMAB vs NEOSTIGMINE METHYLSULFATE

Related Pages

NEMOLIZUMAB Full Profile All Inappropriate schedule of product administration Reports All Drugs Causing Inappropriate schedule of product administration NEMOLIZUMAB Demographics